Product nameAnti-RanBP2 antibody
See all RanBP2 primary antibodies
DescriptionRabbit polyclonal to RanBP2
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Predicted to work with: Chimpanzee
Synthetic peptide within Human RanBP2 aa 2600-2650. The exact sequence is proprietary. NP_006258.3
Database link: P49792
- WB: HeLa whole cell lysate. IP: RanBP2 IP in HeLa whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: Tris buffered saline, 0.1% BSA
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab245563 was affinity purified using an epitope specific to RanBP2 immobilized on solid support.
Our Abpromise guarantee covers the use of ab245563 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000.|
|IP||Use at 2-5 µg/mg of lysate.|
FunctionE3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Could also have isomerase or chaperone activity and may bind RNA or DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1.
PathwayProtein modification; protein sumoylation.
Involvement in diseaseDefects in RANBP2 are the cause of susceptibility to encephalopathy acute necrotizing type 1 (ANE1) [MIM:608033]. A rapidly progressive encephalopathy manifesting in susceptibile individuals with seizures and coma. It can occur within days in otherwise healthy children after common viral infections such as influenza and parainfluenza, without evidence of viral infection of the brain or inflammatory cell infiltration. Brain T2-weighted magnetic resonance imaging reveals characteristic symmetric lesions present in the thalami, pons and brainstem.
Sequence similaritiesContains 1 PPIase cyclophilin-type domain.
Contains 4 RanBD1 domains.
Contains 8 RanBP2-type zinc fingers.
Contains 1 TPR repeat.
DomainContains F-X-F-G repeats.
modificationsPolyubiquitinated by PARK2, which leads to proteasomal degradation.
Cellular localizationNucleus > nuclear pore complex. Cytoplasmic filaments.
- Information by UniProt
- 358 kDa nucleoporin antibody
- ANE1 antibody
- E3 SUMO-protein ligase RanBP2 antibody
All lanes : Anti-RanBP2 antibody (ab245563) at 0.04 µg/ml
Lane 1 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Exposure time: 5 seconds
RanBP2 was immunoprecipitated from HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg per IP reaction; 20% of IP loaded).
ab245563 used for IP at 3 µg/mg lysate. For WB 0.1 µg/ml.
Lane 1: ab245563 IP in HeLa whole cell lysate.
Lane 2: Control IgG in HeLa whole cell lysate.
Chemiluminescence detection: 1 second.
ab245563 has not yet been referenced specifically in any publications.